Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 147.4%

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 14,100 shares, a growth of 147.4% from the June 30th total of 5,700 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 21,400 shares, the short-interest ratio is currently 0.7 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Indaptus Therapeutics in a report on Monday, June 17th.

Indaptus Therapeutics Price Performance

Shares of INDP stock traded up $0.03 during trading hours on Friday, hitting $2.06. 7,310 shares of the company’s stock were exchanged, compared to its average volume of 8,011. The stock’s 50-day moving average is $2.32 and its 200-day moving average is $2.15. Indaptus Therapeutics has a 52 week low of $1.56 and a 52 week high of $4.08.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. Equities research analysts expect that Indaptus Therapeutics will post -1.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.17% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.